ENA-001, a New Chemical Entity (NCE) with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease designation for the Treatment of AoP by the FDA, with eligibility for a priority review voucher (PRV). The compound is also being developed by Enalare for the treatment of post-operative respiratory depression and community drug overdose.
Read Press ReleaseThe Funding Will Accelerate Development of an Intramuscular Formulation of ENA-001, a Novel Agnostic Respiratory Stimulant, for the Potential Treatment of Community Drug Overdose and as a Medical Countermeasure for Mass Casualty Events. The Funding Supports Development of an Intramuscular ENA-001 From Pre-Clinical Toxicology Through Filing for Approval in the United States
Read Press ReleaseDevelopment of a sublingual COVID-19 subunit vaccine: the potential for a better protective efficacy and improved thermal stability during distribution and storage as compared to conventional COVID-19 vaccines
Read Press ReleaseSeattle-based primary cell biology CRO ReachBio and Swiss biotech abc biopply announced today a partnership to jointly co-market their preclinical test models. The two companies plan to support their clients with an even more predictive assay portfolio to further increase the efficiency of their drug discovery and development process.
Read Press ReleaseIn collaboration with Swiss precision manufacturer CSEM, 3Brain AG has announced an exciting 3D microchip for their brain-on-chip portfolio. This first-in-class cell-electronic interface technology will allow scientists to study the complexity of 3D cellular networks at unrivalled scale and precision - and to gain novel mechanistic insights into the inner workings of the most complex structure in the universe: the human brain.
Read Press ReleaseAfter months of experimentation in partnership with some world-class schools of medicine and top-tier diagnostic providers, the much-anticipated T-Cell Test from Hyris, based on innovative qPCR technology, is finally available for the European market with a CE-IVD mark. The new Test will change the way laboratories and diagnostic providers track and monitor T-cell patients' immunity to SARS-CoV-2, leveraging the unique characteristics of the Hyris System™.
Read Press ReleaseLatest milestone brings the Selux Next-Generation Phenotyping (NGP) platform one step closer to impacting patient care with same-shift Antibiotic Susceptibility Testing (AST).
Read Press ReleaseThis is the new fantasy creature from the Phantasticals campaign that Ferrer has relaunched, coinciding with Global Amyotrophic Lateral Sclerosis (ALS) Awareness Day, on June 21. The aim is to raise public awareness of this rare, neurodegenerative, progressive disease that affects the motor neurons in the brain. Ferrer is leading the ADORE Phase III clinical trial to evaluate the safety and efficacy of the investigational drug FNP122 in the treatment of ALS.
Read Press ReleaseA scientific paper recently published in Nature Biotechnology reveals new research regarding how we track and monitor T-cell patients' immunity to SARS-CoV-2, leveraging the unique characteristics of Hyris System™. The study results from a joint effort of an international research team from the Icahn School of Medicine at Mount Sinai, Singapore Duke-NUS Medical School, laboratory diagnostic service providers Synlab, and Hyris.
Read Press ReleaseRecardio Inc., a clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the study results of Recardio's Phase 2 clinical study in Acute Myocardial Infarction will be presented on Saturday, May 21, 2022, during the Latebreaker Session at the World Congress on Acute Heart Failure 2022 in Madrid.
Read Press Release